314 related articles for article (PubMed ID: 27855284)
1. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
Cheng BYH; Nogales A; de la Torre JC; Martínez-Sobrido L
Virology; 2017 Jan; 501():35-46. PubMed ID: 27855284
[TBL] [Abstract][Full Text] [Related]
2. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
[TBL] [Abstract][Full Text] [Related]
3. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
[TBL] [Abstract][Full Text] [Related]
4. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
5. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
6. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC
J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049
[TBL] [Abstract][Full Text] [Related]
7. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
[TBL] [Abstract][Full Text] [Related]
8. Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation.
Sakabe S; Cubitt B; Martinez-Sobrido L; de la Torre JC
J Virol; 2023 Jan; 97(1):e0138522. PubMed ID: 36533953
[TBL] [Abstract][Full Text] [Related]
9. Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).
Shao J; Huang Q; Liu X; Di D; Dileepan M; Brisse M; Ly H; Liang Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462569
[TBL] [Abstract][Full Text] [Related]
10. Reverse Genetics Approaches to Control Arenavirus.
Martínez-Sobrido L; Cheng BY; de la Torre JC
Methods Mol Biol; 2016; 1403():313-51. PubMed ID: 27076139
[TBL] [Abstract][Full Text] [Related]
11. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
de la Torre JC
Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
[TBL] [Abstract][Full Text] [Related]
12. Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models.
Li P; Ke X; Wang T; Tan Z; Luo D; Miao Y; Sun J; Zhang Y; Liu Y; Hu Q; Xu F; Wang H; Zheng Z
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925661
[TBL] [Abstract][Full Text] [Related]
13. Reverse genetics approaches to combat pathogenic arenaviruses.
de la Torre JC
Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590
[TBL] [Abstract][Full Text] [Related]
14. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
15. Envelope exchange for the generation of live-attenuated arenavirus vaccines.
Bergthaler A; Gerber NU; Merkler D; Horvath E; de la Torre JC; Pinschewer DD
PLoS Pathog; 2006 Jun; 2(6):e51. PubMed ID: 16751848
[TBL] [Abstract][Full Text] [Related]
16. Arenavirus reverse genetics for vaccine development.
Ortiz-Riaño E; Cheng BYH; Carlos de la Torre J; Martínez-Sobrido L
J Gen Virol; 2013 Jun; 94(Pt 6):1175-1188. PubMed ID: 23364194
[TBL] [Abstract][Full Text] [Related]
17. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes.
Pinschewer DD; Flatz L; Steinborn R; Horvath E; Fernandez M; Lutz H; Suter M; Bergthaler A
Int Immunol; 2010 Sep; 22(9):749-56. PubMed ID: 20584765
[TBL] [Abstract][Full Text] [Related]
18. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
19. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
